Real-time enrollment status for this congenital erythropoietic porphyria (cep) clinical trial
Current Status
Recruiting
Checked: September 1, 2026 at 4:47 AM UTC
| NCT Number | NCT07024316 |
| Recruiting Status | Recruiting |
| Condition | Congenital Erythropoietic Porphyria (CEP) |
| Phase | PHASE1 |
| Target Enrollment | 6 participants |
| Active Locations | 1 sites in the US |
| Sponsor | Atlas Molecular Pharma |
| Last Updated on CT.gov | March 24, 2026 (Mar 24, 2026) |
As of September 1, 2026: Clinical trial NCT07024316 is currently recruiting participants. This phase1 study for congenital erythropoietic porphyria (cep) is actively seeking new participants at 1 location across the United States. The study is sponsored by Atlas Molecular Pharma. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07024316 is actively recruiting participants as of September 1, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 1 location in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07024316 was last updated Mar 24, 2026 (March 24, 2026). HelloStudys verifies this status automatically.